E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ER-positive, HER2-negative breast cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Early breast cancer in women that is oestrogen receptor positive and human epidermal growth factor receptor negative. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10070577 |
E.1.2 | Term | Oestrogen receptor positive breast cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare the changes in Ki67 proliferation index after 24 weeks treatment with oestrogen suppression therapy with or without palbociclib for patients with an intermediate RS score. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives for the randomised group: 1. To compare the objective radiological response rate as measured by ultrasound after 24 weeks treatment with oestrogen suppression therapy with or without palbociclib. 2. To compare the objective clinical response rate after 24 weeks treatment with oestrogen suppression therapy with or without palbociclib. 3. To compare the proportion of patients who undergo breast conservation after 24 weeks of treatment with oestrogen suppression therapy with or without palbociclib. 4. To compare the proportion of patients with improved surgical outcome after 24 weeks of treatment with oestrogen suppression therapy with or without palbociclib. 5. To compare the pathological complete response (pCR) rate after 24 weeks treatment with oestrogen suppression therapy with or without palbociclib. 6. To compare the proportion of tumours with a Preoperative Endocrine Prognostic Index (PEPI) score of 0 or 1 after 24 weeks of treatment with oestrogen suppressio |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• 18 years of age or older • Histologically confirmed invasive breast cancer • ER positive (Allred ≥3) • HER2 negative per the 2013 ASCO/CAP guidelines • Axillary node negative or positive • Tumour measuring ≥15mm in longest diameter as measured clinically or radiologically* or any size tumour with axillary node involvement • Candidate for neoadjuvant endocrine therapy or chemotherapy • Pre- or postmenopausal women Postmenopausal status will be defined by the presence of any one of the following criteria: ≥55 years of age with an intact uterus and amenorrhoea ≥12 months at the time of diagnosis <55 years with no menses for at least 12 months prior to study entry and documented or current FSH and oestradiol levels within the postmenopausal range (as per local institutional/laboratory standard >18 years with prior hysterectomy with intact ovaries and with a documented or current FSH and oestradiol level within the postmenopausal range (as per local institutional/laboratory standard) >18 years with prior bilateral oophorectomy • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 • Adequate bone marrow function defined by Hb≥10 g/dl, ANC >1.5 x109, PLT≥100 x109/L. • Adequate renal function defined by a serum creatinine ≤1.5 x ULN. Adequate liver function defined by total bilirubin ≤ 1.5 ULN (patients with Gilbert’s syndrome exempted), either ALT or AST ≤1.5 ULN and ALP ≤1.5 ULN • No contraindications to receiving palbociclib • Written informed consent, able to comply with treatment and follow-up.
|
|
E.4 | Principal exclusion criteria |
• Inflammatory breast cancer • Evidence of metastatic disease prior to 21-gene recurrence score assay testing • Any history of invasive malignancy within 5 years of starting study treatment (other than adequately treated basal cell carcinoma or squamous cell carcinoma of the skin and cervical carcinoma in situ) • Surgical axillary staging procedure prior to study procedure (with the exception of FNA or core biopsy) • Evidence of bleeding diathesis • Prior endocrine therapy or chemotherapy for breast cancer • Concomitant use (defined as use within 4 weeks prior to entry) of HRT or any other oestrogen-containing medication or supplement (including vaginal oestrogens and phytoestrogens) • Uncontrolled abnormalities of serum potassium, sodium, calcium or magnesium levels • Use of CYP3A inhibitors or inducers • Evidence of uncontrolled active infection • Evidence of significant medical condition or laboratory findings which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial • Pregnant or breastfeeding
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
For the RCT the primary outcome is the change in level of proliferation marker Ki67 from baseline to 24 weeks.
Note that for the observational cohort all outcomes are secondary, although the change in level of proliferation marker Ki67 will be assessed. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline tissue sample taken from diagnostic biopsy (up to 28 days prior to study registration/randomisation) and a further tissue sample taken the end of treatment at 24 weeks. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints for the RCT interventional cohort i.e. the intermediate recurrence score group treated with oestrogen suppression therapy or oestrogen suppression plus palbociclib are as follows: • Objective of radiological response as measured by ultrasound after 24 weeks of treatment according to the ECOG criteria. • Objective clinical response after 24 weeks of treatment according to the ECOG criteria. • Breast conservation after 24 weeks of treatment. • Improved surgical outcome after 24 weeks of treatment. • Pathological complete response (pCR) after 24 weeks of treatment. • Preoperative Endocrine Prognostic Index (PEPI) score after 24 weeks. • Adjuvant chemotherapy after surgery. • Safety and tolerability in terms of: o grade 3+ toxicity classified by NCI-CTCAE v 4.0. o serious adverse events o withdrawal from trial treatment due to toxicity o experience of delay to scheduled surgery due to treatment related toxicities
Secondary endpoints for the observational cohort i.e. low recurrence score group treated with oestrogen suppression therapy and high recurrence score group treated with chemotherapy: • Objective of radiological response as measured by ultrasound after 24 weeks of treatment according to the ECOG criteria. • Objective clinical response after 24 weeks of treatment according to the ECOG criteria. • Breast conservation after 24 weeks of treatment. • Improved surgical outcome after 24 weeks of treatment. • Pathological complete response (pCR) after 24 weeks of treatment. • Preoperative Endocrine Prognostic Index (PEPI) score after 24 weeks. • Adjuvant chemotherapy after surgery. • Level of Ki67 proliferation marker at baseline and at 24 weeks.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline and end of treatment at 24 weeks/surgery |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Control arm is oestrogen suppression therapy alone |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be the last visit (4-weeks post-surgery) of the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 1 |